GlaxoSmithKline has halted the development of SRT501, an experimental drug based on resveratrol, but that doesn't mean the pharmaceutical firm has stopped developing any medicines based on the compound. Wine Spectator assistant editor Stephanie Cain explains.
For the full article, check out the new issue of Wine Spectator, on newsstands February 1, 2011.
Do you have a Wine Spectator magazine subscription? Save 50% on your Online Membership right now!
Sips & Tips | Wine & Healthy Living
Video Theater | Collecting & Auctions